Note: Unless otherwise specified, blank values indicate missing data.			
Data Items	**Variable Name**	**Coding/Description**	**Note**
Patient identifier	uid	Unique ID, not ECOG case ID	
Patient identifier	group_uid	A blinded ID generated by ECOG-ACRIN	
Treatment arm	ASSIGNED_TX_ARM	A = ADT + docetaxel; B = ADT alone	
Stratification factor - age	STRAT_AGE	1 = ≥70; 2 = <70	
Stratification factor - performance status	STRAT_PS	1 = PS 0-1; 2 = PS 2	
Stratification factor - intend to use combined androgen blockade > 30 days from start of treatment	STRAT_CAB	1 = Intend to use combined androgen blockade > 30 days from start of treatment; 2 = No intent to use combined androgen blockade > 30 days from start of treatment	
Stratification factor - prior adjuvant hormonal therapy	STRAT_ADJHT	1 = >12 months; 2 = ≤12 months	
Stratification factor - will patient receive FDA approved drugs for delaying skeletal related events	STRAT_SRE	1 = No; 2 = Yes	
Stratification factor - volume of disease	STRAT_VOL	1 = high; 2 = low	
Eligibility status	ELIG_THIS_STEP_YN	1 = ineligible; 2 = eligible; 99 = eligibility status not finalized	
Race	RACE	1 = white; 3 = black; 4 = other; -1 = unknown	
Volume of disease per CRF	dz_extent	High = high volume; Low = low volume	
Presence of visceral disease	visc_dz	0 = No; 1 = Yes; 999 = N/A	Presence of visceral disease is only available among patients with high volume disease.
ECOG performance status per CRF	PS		
Baseline PSA value	baseline_PSA	Value in ng/mL	
Age at randomization	age	Value in years (capped at 90)	Ages above 89 are coded as 90.
Gleason score	gleason	Ranging 2-10	
Prior local treatment	prior_local_tx	0 = no local treatment; 1 = prostatectomy; 2 = definitive RT	
Prior adjuvant hormonal therapy	prior_adj_HT	0 = No; 1 = Yes	
ADT started prior to randomization	ADT_bf_rando	0 = No; 1 = Yes	

Data Items	Variable Name	Coding/Description	Note
Time from ADT to randomization	ADT2Rando_mo	Value in months; 999 = N/A	Time interval from ADT start date to randomization date with randomization date as the origin of time; only available among patients who started ADT prior to randomization
Dose modifications/additions/omissions to protocol treatment	MODS_ADD_OMIT_YN	1 = No; 2 = Yes; 999 = N/A	Only among Arm A patients
Number of treatment cycles received	TOTAL_CYC_NUM	Ranging 1-6; 999 = N/A	Only among Arm A patients
Whether patient received protocol therapy	TX_YN	1 = No; 2 = Yes; 999 = N/A	Only among Arm A patients
Overall survival	os	Value in months	Time interval from randomization to death or date last known alive; as of database on 12/23/2013
Survival status	dead	1 = dead; 0 = censor	As of database on 12/23/2013
Cause of death	COD	1 = due to protocol treatment; 2 = due to prostate cancer; 3 = other cause; -1 = unknown; -2 = missing; 999 = N/A	Only among patients who have died as of 12/23/2013
Time to castration-resistant prostate cancer	TT_CRPC	Value in months	Time interval from randomization to PSA progression or clinical progression, whichever occurred first. Patients without documented progression were censored at the date of last disease assessment. As of database on 12/23/2014
Time to clinical progression	TT_clinical_PD	Value in months	Time interval from randomization to clinical progression. Patients without documented progression were censored at the date of last disease assessment. As of database on 12/23/2014.

Data Items	Variable Name	Coding/Description	Note
Progression-free survival	PFS	Value in months	Time interval from randomization to PSA progression, clinical progression or death, whichever occurred first, or time from randomization until date last known progression-free. Patients who died without documented progression and the death occurred more than 3 months after the date of last disease assessment were censored at the date of last disease assessment. As of database on 12/23/2014.
Castration-resistant prostate cancer	CRPC	1 = PSA progression or clinical progression; 0 = censor	As of database on 12/23/2014
Clinical progression	clinical_PD	1 = clinical PD; 0 = censor	As of database on 12/23/2014
Progression-free survival event	PFS_event	1 = event; 0 = censor	As of database on 12/23/2014
PSA complete response at 6 months	PSACR_6mo	0 = No; 1 = Yes	
PSA complete response at 12 months	PSACR_12mo	0 = No; 1 = Yes	
Subsequent treatment of docetaxel after progression	Taxotere	0 = No; 1 = Yes	
Subsequent treatment of docetaxel before progression	Taxotere_bfPD	0 = No; 1 = Yes	
Subsequent treatment of cabazitaxel after progression	cabazitaxel	0 = No; 1 = Yes	
Subsequent treatment of mitoxantrone and/or platinum after progression	mito_platinum	0 = No; 1 = Yes	
Subsequent treatment of abiraterone and/or enzalutamide after progression	abi_enza	0 = No; 1 = Yes	
Subsequent treatment of antiandrogen and/or ketoconazole after progression	aa_keto	0 = No; 1 = Yes	
Subsequent treatment of Sipuleucel T after progression	provenge	0 = No; 1 = Yes	

Data Items	Variable Name	Coding/Description	Note
Subsequent treatment of radiotherapy after progression	RT	0 = No; 1 = Yes	
Number of life-prolonging treatments administered post progression	num_life_prol_3group	0 = 0; 1 = 1; 2 = 2 or more	Life-prolonging treatments include docetaxel, cabazitaxel, abiraterone, enzalutamide and sipuleucel T.
Included in the primary analysis	include	0 = No; 1 = Yes	